Interleukin Inhibitors in Cytokine Release Syndrome and Neurotoxicity Secondary to CAR-T Therapy

Introduction: Chimeric antigen receptor T-cell (CAR-T) therapy is an innovative therapeutic option for addressing certain recurrent or refractory hematological malignancies. However, CAR-T cells also cause the release of pro-inflammatory cytokines that lead to life-threatening cytokine release syndr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferreros, Puri, Trapero, Isabel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326641/
https://www.ncbi.nlm.nih.gov/pubmed/35892735
http://dx.doi.org/10.3390/diseases10030041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326641/
https://www.ncbi.nlm.nih.gov/pubmed/35892735
http://dx.doi.org/10.3390/diseases10030041

Ejemplares similares